Ulrikka Nygaard and Nadja Vissing on antibiotic treatment in children with high-risk febrile neutropenia
Failed to add items
Add to basket failed.
Add to wishlist failed.
Remove from wishlist failed.
Adding to library failed
Follow podcast failed
Unfollow podcast failed
Ulrikka Nygaard and Nadja Vissing on antibiotic treatment in children with high-risk febrile neutropenia
-
Narrated by:
-
By:
This episode considers how antibiotic use can be safely reduced in children in high-risk scenarios or with severe infections. To discuss this we are joined by Dr Nadja Vissing and Dr Ulrikka Nygaard, paediatric infectious disease specialists from Copenhagen University Hospital, who led a randomized controlled trial in Denmark evaluating the early discontinuation of empirical antibiotics versus extended treatment in children with cancer and high-risk febrile neutropenia. We hear about the importance of this trial for children with cancer and their families as well as for broader antimicrobial stewardship.
We discuss other recent RCTs that are informing safely reducing antibiotic exposure in children with urinary tract infections, uncomplicated bone and joint infections and probable early onset neonatal sepsis. Nadja and Ulrikka share with listeners their take home messages related to antibiotic decision-making from these trials along with words of wisdom and motivation for other paediatric clinical trialists.
Click here to read the full article:
https://www.thelancet.com/journals/lanchi/article/PIIS2352-4642(26)00039-8/fulltext